We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Priveterra Acquisition Corporation II | NASDAQ:PMGMU | NASDAQ | Trust |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.96 | 8.99 | 13.21 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR 12(g) OF THE
SECURITIES EXCHANGE ACT OF 1934
AEON Biopharma, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 85-3940478 |
(State of incorporation or organization) | (I.R.S. Employer Identification No.) |
5 Park Plaza, Suite 1750 Irvine, California |
92614 |
(Address of principal executive offices) | (Zip Code) |
Securities to be registered pursuant to Section 12(b) of the Act:
Title for each class to be so registered |
Name of each exchange on which each class is to be registered |
Class A Common Stock, par value $0.0001 per share | New York Stock Exchange American |
Warrants, each whole warrant exercisable to purchase one share of Class A Common Stock at an exercise price of $11.50 per share | New York Stock Exchange American |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), please check the following box. x
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), please check the following box. ¨
Securities Act registration statement file number to which this form relates: 333-252310; 333-269006 (if applicable)
Securities to be registered pursuant to Section 12(g) of the Act: N/A
Explanatory Note
This Registration Statement on Form 8-A is being filed by AEON Biopharma, Inc. (the “Company”), formerly known as Priveterra Acquisition Corp., with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the transfer of the listing of the Company’s Class A common stock, par value $0.0001 per share (“Company Common Stock”), and its warrants to purchase shares of Company Common Stock (the “Company Warrants”) from The Nasdaq Stock Market LLC to the NYSE American LLC.
Item 1. Description of Registrant’s Securities to be Registered.
The securities to be registered hereby are the Company Common Stock and Company Warrants.
The description of the Company Common Stock and Company Warrants registered hereunder is set forth under the caption “Description of New AEON’s Securities After the Business Combination” in the Company’s definitive proxy statement/prospectus, dated as of May 12, 2023 (File No. 333-269006) and filed with the SEC on May 12, 2023 (including any subsequent supplements or amendments with respect to the description of the Company Common Stock and Company Warrants), and is incorporated herein by reference.
Item 2. Exhibits.
In accordance with the “Instructions as to Exhibits” with respect to Form 8-A, no exhibits are required to be filed as part of this registration statement because no other securities of the registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: July 21, 2023
AEON Biopharma, Inc. | |||
By: | /s/ Marc Forth | ||
Name: | Marc Forth | ||
Title: | Chief Executive Officer |
1 Year Priveterra Acquisition C... Chart |
1 Month Priveterra Acquisition C... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions